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OBJECTIVE — There are limited data on the risk of pulmonary disease in patients with
diabetes. The aim of this study was to evaluate and compare the incidence of asthma, chronic
obstructive pulmonary disease (COPD), pulmonary ﬁbrosis, pneumonia, and lung cancer in
patients with and without a diagnosis of diabetes.
RESEARCH DESIGN AND METHODS — We conducted a retrospective, longitudinal
cohort study using the electronic records of a large health plan in northern California. Age and
sex data were available for all cohort members (n  1,811,228). Data on confounders were
available for a subcohort that responded to surveys (n  121,886), among whom Cox propor-
tional hazards regression models were ﬁt.
RESULTS — Age-andsex-adjustedincidenceratesand95%CIswerecalculatedformembers
with and without diabetes in the full cohort and the subcohort. No difference was observed for
lung cancer, but the incidence of asthma, COPD, ﬁbrosis, and pneumonia was signiﬁcantly
higher in those members with a diagnosis of diabetes. These differences remained signiﬁcant in
regression models adjusted for age, sex, race/ethnicity, smoking, BMI, education, alcohol con-
sumption, and outpatient visits (asthma hazard ratio [HR] 1.08 [95% CI 1.03–1.12], COPD HR
1.22 [1.15–1.28], pulmonary ﬁbrosis HR 1.54 [1.31–1.81], and pneumonia HR 1.92 [1.84–
1.99]). The risk of pneumonia and COPD increased signiﬁcantly with increasing A1C.
CONCLUSIONS — Individuals with diabetes are at increased risk of several pulmonary
conditions (asthma, COPD, ﬁbrosis, and pneumonia) but not lung cancer. This increased risk
may be a consequence of declining lung function in patients with diabetes.
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C
hronic complications of diabetes in-
clude a number of pathological
changes that involve small and large
blood vessels, cranial and peripheral
nerves, the skin, and the retina of the eye.
The lung is also a target organ for diabetic
microangiopathy in patients with both
type 1 and type 2 diabetes (1), and decre-
ments in lung function have been re-
ported among patients with diabetes over
the past two decades (2–9).
Decrements in the lung function of
patients with diabetes are believed to be
the consequence of biochemical alter-
ations in the connective tissue constitu-
ents of the lung, particularly collagen and
elastin, as well as microangiopathy due to
the nonenzymatic glycosylation of pro-
teins induced by chronic hyperglycemia
(8,10). Alterations in collagen and elastin
and microangiopathy result in thickening
of the alveolar epithelial basal lamina,
leading to reduced pulmonary capacity
for the diffusion of carbon monoxide
(8,10). Previous studies investigating the
potential association between diabetes
and lung cancer have been inconclusive
(11–13). No studies have examined the
incidence of pulmonary outcomes, other
than lung cancer (11), in people with
diabetes compared with those without
diabetes. The aim of this study was to
evaluate and compare the incidence of
asthma, chronic obstructive pulmonary
disease (COPD), pulmonary ﬁbrosis,
pneumonia, and lung cancer using the
electronic medical records of 1,811,228
members of a large group practice, pre-
paid health plan in northern California;
77,637 members (4.3%) had been diag-
nosedwithdiabetesand1,733,591mem-
bers (95.7%) had not.
RESEARCH DESIGN AND
METHODS— The Kaiser Permanente
Medical Care Program in northern Cali-
fornia (KPNC) is a large group-practice
prepaid health plan that provides com-
prehensive medical services to a 14-
county region. Approximately 30% of the
population that resides in the area served
by the KPNC are members. From the re-
sults of the 1990 and 2000 censuses, we
know that the KPNC membership is rep-
resentative of the population living in the
14-county geographical area with regard
to demographic characteristics, race or
ethnicity, and socioeconomic status, ex-
cept that the very poor and the very
wealthy are underrepresented (14,15).
Full cohort
Aretrospective,longitudinalcohortstudy
design was used to investigate the inci-
dence of asthma, COPD, pulmonary
ﬁbrosis, pneumonia, and lung cancer by
diabetes status among 77,637 members
with a diagnosis of diabetes and
1,733,591 members without a diagnosis
ofdiabeteswhowereaged18yearsasof
1January1996.Membersweredeﬁnedas
havingadiagnosisofdiabetesiftheywere
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of 1 January 1996. Those not included in
the diabetes registry were coded as not
having diabetes. The diabetes registry
started in 1994 and identiﬁes members
with diabetes from automated sources;
the registry includes members with 1)
pharmacyprescriptionsfordiabetesmed-
icationsorsupplies,2)abnormalA1Cval-
ues (6.7%), 3) primary or secondary
hospital discharge diagnoses of diabetes,
and 4) emergency department visits for
which a physician diagnosis of diabetes
waslisted.Thediabetesregistryhasasen-
sitivity of 97% (16).
Outcome identiﬁcation
To identify cases of asthma, COPD, pul-
monary ﬁbrosis, and pneumonia, cohort
memberswerelinkedtotheKPNChospi-
tal discharge database and the member-
ship mortality ﬁles by their unique
medical record number. The hospital dis-
charge database, a complete database of
all hospitalizations occurring at any
KPNC hospital, codes diagnoses accord-
ing to the ICD-9. Deaths among KPNC
members in the mortality ﬁles are identi-
ﬁed through an annual, automated link-
age to the computerized State of
California Death Certiﬁcate ﬁles, which
also use ICD-9 codes (17).
To identify more severe cases of
asthma, COPD, pulmonary ﬁbrosis, and
pneumonia, the case deﬁnition was re-
stricted to include only those that re-
quired hospitalization and had the
pulmonary outcome of interest listed as
the primary discharge diagnosis or in-
stances in which the outcome of interest
was listed as the underlying cause of
death. The ﬁrst diagnosis of the pulmo-
nary outcome of interest, as identiﬁed by
either database, was used as the date of
diagnosis.Weusedthefollowingcodesto
identify cases: asthma, ICD-9 493;
COPD,ICD-9491,492,and494;pulmo-
nary ﬁbrosis, ICD-9 515 (chronic post in-
ﬂammatory) and 516.3 (idiopathic), and
pneumonia, ICD-9 480 through 486 and
487.0.
Cases of lung cancer were identiﬁed
through the KPNC Cancer Registry, which
is responsible for the identiﬁcation and re-
porting of all new cancer diagnoses. The
registry transmits these data to the Califor-
nia Cancer Registry and the Surveillance,
Epidemiology and End Results program of
the National Cancer Institute.
Cohort of survey responders
A similar study was conducted among a
subsample of members who had re-
sponded to surveys sent out by the
healthplan(n  121,886),thusprovid-
ing data on potential confounders.
These surveys included the diabetes
registry survey (DRS) and the member
health survey (MHS). The DRS was
mailed between 1995 and 1997 to all
health plan members, aged 18 years,
who had a diabetes diagnosis, as identi-
ﬁed by the diabetes registry.
The MHS questionnaires were mailed
out in 1993, 1996, and 1999 to random
samples of KPNC members, aged 18,
stratiﬁed by age and KPNC facility. MHS
responders who were also in the diabetes
registry or reported having had a diagno-
sis of diabetes on the MHS were not in-
cluded in the diabetic group. Data on
potential confounding factors were taken
from the earliest MHS completed. Mem-
bers who responded to both surveys were
included in the diabetic group, with data
on potential confounders taken from the
DRS. Members stating on the MHS that
they had diabetes but who did not re-
spond to the DRS were excluded, as were
those who were no longer members of
Kaiser Permanente at the survey date.
Covariates
In addition to the confounding variables
age and sex, which were available for all
members in the electronic databases, data
on the following potential confounding
factors were collected in the two surveys:
race/ethnicity (non-Hispanic white, Afri-
can American, Hispanic, Asian or Paciﬁc
Islander, other, and missing), education
(some high school or high school gradu-
ate, some college, college graduate or
postcollege, and missing), alcohol con-
sumption (never, past, current, and miss-
ing),smoking,height,andweight.Health
plan members were categorized accord-
ing to their smoking status at the time of
the survey as having never smoked, past
smoker, and current smoker. BMI was
calculated as weight in kilograms divided
by the square of height in meters. Data on
A1C (continuous), measured within 1
year () of the baseline date, and the
number of outpatient visits occurring in
the 12 months before baseline (0 as the
reference, 1–2, 3–4, 5–9, 10–19, 20
visits, and missing) were obtained from
the electronic records.
Statistical analyses
For each pulmonary outcome of interest,
crude incidence rates were calculated
among cohort members without any in-
patientoroutpatientdiagnosesoftheout-
come of interest before baseline and
stratiﬁedbydiabetesstatusatthebaseline
date of 1 January 1996, with 95% CIs
based on the exact Poisson distribution.
Age-andsex-adjustedincidenceratesand
95% CIs were calculated and stratiﬁed by
diabetes status at baseline, with attention
toproperallocationofperson-timeacross
age categories as the cohort was followed
throughcalendartime.Thedirectmethod
of adjustment for age and sex was used,
with the U.S. 2000 Census age-sex distri-
butionamongindividualsaged18years
as the standard population.
For incidence rate calculations in the
full cohort, members began contributing
person-time on 1 January 1996. In anal-
yses that included only survey respond-
ers, DRS respondents began contributing
person-time on the date of the DRS and
MHS respondents began contributing
person-time on the date the earliest MHS
wascompleted.Memberswhocompleted
the1993DRSbegancontributingperson-
time on 1 January 1996. All members
contributed person-time to the denomi-
nator until one of the following occurred:
1) the end of the study (31 December
2005); 2) a diagnosis of asthma, pneumo-
nia, pulmonary ﬁbrosis, COPD, or lung
cancer; 3) death; or 4) termination of
membership in the Kaiser Permanente
Medical Care Program (via electronic
membership ﬁles), whichever occurred
ﬁrst. No complications or events, other
than death, censored patients in the cal-
culation of the incidence rates of other
pulmonary outcomes. For example, a pa-
tient remained at risk and continued to
contribute person-time for events other
than pneumonia after an incident case
of pneumonia was recorded. Members
without diabetes as of 1 January 1996
stopped contributing person-time if
they developed diabetes over the course
of the follow-up period. The statistical
signiﬁcance of the difference in inci-
dence rates between those with and
without a diagnosis of diabetes was as-
sessed via Poisson regression, control-
ling for age and sex.
In the subcohort of survey respon-
dents, the association between diabetes
and each pulmonary outcome of interest
was assessed using Cox proportional haz-
ards regression models, providing point
and interval estimates of the relative haz-
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ated with diabetes status, with control
for potential confounders. Model 1 in-
cludedage,sex,andrace/ethnicity;model
2 included the model 1 covariates and
smoking, BMI, education, alcohol con-
sumption, and the number of outpatient
visits occurring in the 12 months before
the baseline. Among those with a diagno-
sisofdiabetes,amodelthatincludedallof
the model 2 covariates and A1C at base-
line, a continuous variable, was con-
structed. Assessment of departure from
themodelassumptionsincludeddiagnos-
tic plots of weighted residuals and tests
for interaction between exposure and
time. All statistical analyses were con-
ducted in SAS.
This study was approved by the hu-
man subjects committee of the Kaiser
Foundation Research Institute.
RESULTS— The full cohort of KPNC
members included 77,637 members with
a diagnosis of diabetes (median age 60.0
years) and 1,733,591 members without
diabetes (median age 43.0 years). Those
withdiabetestendedtobemale(53.4%of
those with diabetes vs. 47.3% of those
without). Table 1 displays the character-
istics of the subcohort of survey respond-
ers, which included 70,645 members
with a diagnosis of diabetes (median age
60.0 years) and 51,241 members without
diabetes (median age 51.0 years). Survey
responders with diabetes tended to have
higherBMI,tobelongtoaminorityracial-
ethnicgroup,andtobelesseducatedthan
responders without diabetes.
Age- and sex-adjusted incidence
rates, stratiﬁed by diabetes status at base-
line, were calculated for each pulmonary
outcome (Table 2). In the full cohort, a
signiﬁcantlyhigherincidenceofeachpul-
monarycondition,exceptforlungcancer,
was observed in health plan members
with a diagnosis of diabetes compared
withmemberswithoutdiabetes.InaPois-
son regression that controlled for sex and
age, members with diabetes had a higher
incidence of each pulmonary condition,
except for lung cancer, compared with
members without diabetes (likelihood ra-
tio test, P  0.01 for all pulmonary con-
ditions except for lung cancer and P 
0.74 for lung cancer). In the subcohort of
survey responders, the incidence of every
pulmonary condition, except for lung
cancer, was also signiﬁcantly higher
among survey responders with a diagno-
sis of diabetes than among survey re-
sponders without diabetes (Table 2).
In the subcohort of survey respond-
ers, after adjustment for age, sex, race/
ethnicity, smoking, BMI, education,
alcoholconsumption,andnumberofout-
patient visits occurring in the 12 months
before the baseline, health plan members
with a diagnosis of diabetes had a signiﬁ-
cantly higher risk of every pulmonary
condition, except for lung cancer, com-
pared with health plan members without
diabetes (Table 3). Because data on med-
ical visits only became available in the
electronic medical record in 1994, data
on the number of outpatient visits occur-
ringbeforethebaselinewerenotavailable
for health plan members who responded
to the 1993 MHS, representing one-third
of the survey responders without diabe-
Table 1—Characteristics of survey responders by diabetes status: KPNC, 1993–1999
Diagnosed
diabetes
Without
diabetes
n 70,645 51,241
Male sex 53.1 44.9
Age (years)
40 7.1 27.5
40–49 15.91 19.97
50–59 25.03 15.76
60–69 27.94 16.18
70 24.0 20.6
BMI (kg/m
2) 29.80  6.48 26.06  5.14
25 19.74 45.93
25–26.9 12.88 16.85
27–29.9 18.61 16.60
30 35.34 16.70
Missing 13.43 3.91
Race/ethnicity
White 57.88 72.04
African American 12.92 5.83
Hispanic 13.16 7.95
Asian/Paciﬁc Islander 12.63 11.39
Other 3.22 2.58
Missing 0.17 0.22
Education
Some high school or high school graduate 40.24 26.15
Some college 27.21 40.01
College graduate or postcollege 21.33 32.96
Missing 11.23 0.88
Alcohol consumption
Never 18.05 10.68
Past 23.95 14.50
Current 43.37 72.18
Missing 14.63 2.64
Smoking
Never 42.70 56.81
Past smoker 35.41 29.05
Current smoker 10.52 12.46
Missing 11.38 1.68
No. outpatient visits in the 12 months
before baseline
0 13.50 6.66
1–2 22.25 17.31
3–4 18.80 13.93
5–9 26.51 17.54
10–19 14.65 9.05
20 4.29 2.25
Missing 0 33.3
Data are % or means  SD.
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sons without diabetes who responded to
the 1993 MHS, the associations between
diabetes and the pulmonary outcomes
were similar in direction and strength to
the estimates presented in Table 3 (data
not shown). Analyses restricted to those
survey responders with a diagnosis of di-
abetes demonstrated a signiﬁcantly in-
creased risk of COPD and pneumonia for
each unit increase in baseline A1C (haz-
ard ratio [HR] 1.03 [95% CI 1.01–1.04]
and 1.06 [1.05–1.07], respectively; both
P0.002),butnosuchassociationswere
observed for asthma and ﬁbrosis.
CONCLUSIONS — We found that
the incidence of asthma, COPD, pulmo-
nary ﬁbrosis, and pneumonia, but not of
lung cancer, was greater in those with a
diagnosis of diabetes than in those with-
out diabetes. These ﬁndings were consis-
tent through out all of our analyses,
whetherconductedamongthefullcohort
or the subcohort of survey responders,
before and after adjustment for relevant
confounders. There was a signiﬁcant in-
crease in the risk of COPD and pneumo-
nia with increasing baseline A1C among
patients with diabetes. No such associa-
tions with asthma and ﬁbrosis were ob-
served, suggesting that these conditions
might be related to factors other than gly-
cemic control that are associated with
diabetes.
Our results are consistent with those
of a study by Koskinen et al. (18), in
which the authors examined the rates of
death among people in Finland receiving
medication for diabetes compared with
rates for the rest of the population. Koski-
nen et al. (18) found more deaths from
respiratorydiseasesamongpeoplereceiv-
ing diabetes medication than in the rest
of the population. Consistent with the
ﬁndingsofthepresentstudy,therewasno
difference between the groups in deaths
from lung cancer. These authors also
examined COPD separately from other
respiratory diseases and found no differ-
ence in mortality between those receiving
diabetes medication and the rest of the
population.InthestudyofKoskinenetal.
(18), only individuals receiving medica-
tion for diabetes were classiﬁed as having
the disease, so misclassiﬁcation of diabe-
tesstatusislikely,particularlyamongper-
sonswithtype2diabetes.Inaddition,the
authors had no information on smoking
status.Smokinghasbeenshowntobeless
frequent among patients with diabetes
thaninthegeneralpopulation(19,20),so
the results of Koskinen et al. are difﬁcult
to interpret.
Results of previous studies investigat-
ing the potential association between dia-
betes and lung cancer have been
inconclusive (11–13). Our ﬁndings are
consistent with the results of Hall et al.
(11), who also found no increased risk of
lung cancer in patients with diabetes. In
fact,the95%CIsfortheHRsestimatedby
Halletal.(11)overlapthoseofthecurrent
study. In contrast to these ﬁndings, Han-
bali et al. (12) reported that diabetes was
associated with a lower risk of metastasis
in patients with non–small-cell cancer of
the lung but not lower mortality. Win
et al. (13) also recently reported that dia-
betes was a strong predictor of poor over-
all survival in patients with potentially
curable lung cancer.
Kornum et al. (21) conducted a case-
controlstudytoestimatetheriskofpneu-
monia-related hospitalization in patients
with diabetes. In accordance with the
present study, the authors found that
both type 1 and type 2 diabetes were sig-
niﬁcantly associated with an increased
risk of pneumonia-related hospitaliza-
tion; poor glycemic control was also
found to increase the risk of pneumonia-
related hospitalization (21). These ﬁnd-
ings are consistent with an in vitro study
reporting an association between hyper-
glycemia and abnormalities in neutrophil
function, such as impaired chemotaxis,
phagocytes, and bacterial killing (22).
In a cross-sectional analysis adjusted
for age, sex, education, smoking, and
BMI, Methvin et al. (23) found that indi-
viduals with restricted pulmonary func-
tion, the most impaired category of the
Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria, were sig-
niﬁcantly more likely to have comorbid
diabetes. In another cross-sectional anal-
ysis, Gulcan et al. (24) found that fasting
and 2-h blood glucose values were signif-
icantly higher in patients with asthma
bronchialethanincontrolsubjects.How-
ever,theauthorsattributedthisdifference
Table 2—Age- and sex-adjusted incidence rate (per 1,000 person-years) of each pulmonary
outcome in all KPNC members aged >18 years, by diabetes status
Full cohort Survey responder
Pneumonia*
No diabetes 2.27 (2.24–2.29) 1.96 (1.85–2.08)
Diabetes 5.88 (5.56–6.21) 5.76 (5.40–6.11)
Asthma*
No diabetes 0.22 (0.21–0.23) 0.16 (0.12–0.21)
Diabetes 0.48 (0.36–0.61) 0.41 (0.31–0.53)
COPD*
No diabetes 0.60 (0.59–0.62) 0.52 (0.47–0.58)
Diabetes 0.91 (0.80–1.04) 0.87 (0.75–0.98)
Fibrosis*
No diabetes 0.09 (0.09–0.10) 0.10 (0.07–0.13)
Diabetes 0.14 (0.12–0.16) 0.13 (0.11–0.16)
Lung cancer†
No diabetes 0.51 (0.50–0.52) 0.66 (0.60–0.73)
Diabetes 0.47 (0.44–0.50) 0.66 (0.62–0.71)
Dataareage-andsex-adjustedrates(95%CI).*Listedastheprimarydischargediagnosisorunderlyingcause
of death in the Kaiser Permanente databases. †Identiﬁed through the KPNC Cancer Registry.
Table3—HRsand95%CIfortheassociationbetweeneachpulmonaryconditionanddiabetes
status among KPNC survey responders
Model 1* Model 2†
Asthma‡ 2.21 (1.72–2.85) 1.08 (1.03–1.12)
COPD‡ 1.57 (1.40–1.77) 1.22 (1.15–1.28)
Fibrosis‡ 1.64 (1.23–2.18) 1.54 (1.31–1.81)
Pneumonia‡ 2.47 (2.32–2.62) 1.92 (1.84–1.99)
Lung cancer§ 1.05 (0.94–1.17) 1.10 (0.96–1.26)
*Adjusted for age, sex, and race/ethnicity. †Adjusted for age, sex, race/ethnicity, smoking, BMI, education,
alcohol consumption, and number of outpatient visits. ‡Primary discharge diagnosis or underlying cause of
death in the Kaiser Permanente databases. §Identiﬁed through the KPNC Cancer Registry.
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tance in the asthmatic patients. No previ-
ous studies have examined the incidence
of COPD and asthma in individuals with
and without diabetes.
The observed association between di-
abetes and COPD in the present study
might be explained by the increased oc-
currence of pneumonia in patients with
diabetes, as well as decreased pulmonary
function related to hyperglycemia (8,10).
The Fremantle Diabetes Study (5) pro-
spectively examined the relationship be-
tween type 2 diabetes, glycemic control,
andlungfunction.Theauthorsfoundthat
patients with type 2 diabetes had signiﬁ-
cantly lower spirometric values than pre-
dicted for patients of the same age, sex,
and height. Glycemic exposure also
emergedasaconsistentlystrong,negative
predictor of follow-up lung function after
adjustment for confounding variables,
leading the authors to conclude that re-
duced lung volume and airﬂow limita-
tions might be complications of type 2
diabetes. The Rancho Bernardo Study
(25) showed no association between pul-
monary function and known or newly di-
agnosed type 2 diabetes in analyses of
older men and women, adjusted for age,
height,andcigarettesmoking.Therewere
signiﬁcant correlations between fasting
plasma glucose levels and spirometric
measurements only in nondiabetic men,
suggesting that the deleterious effects of
glycemia may precede diabetes. Litonjua
et al. (2) also found that men predisposed
to develop diabetes had decreased lung
function years before the diagnosis of
diabetes.
Our study has several strengths. Be-
cause smoking has been shown to be less
frequent among people with diabetes
than in the general population (19,20)
and obesity is a risk factor for developing
bothpulmonarydiseaseandtype2diabe-
tes, it is essential that any assessment of
the incidence of pulmonary conditions in
people with and without diabetes ac-
counts for these factors. We had data on
smoking and BMI for the cohort of survey
responders, so we were able to compare
the incidences of the pulmonary out-
comesamongsurveyresponderswithand
withoutadiagnosisofdiabeteswhilecon-
trollingforthesekeyandotherconfound-
ing factors.
There are also several weaknesses to
benoted.Themisclassiﬁcationofdiabetes
status is a potential issue in the present
study, as we were only able to include
health plan members with a diagnosis of
diabetes. It is possible that members who
had never been tested for diabetes did, in
fact, have the disease. Such misclassiﬁca-
tion suggests that the true differences be-
tween the incidences of the pulmonary
outcomes and the HRs for the association
betweendiabetesandthepulmonaryout-
comes are greater than we reported. In
addition, data on confounding factors
were taken from surveys that were mailed
to members between 1995 and 1997 for
those with a diagnosis of diabetes and in
1993, 1996, or 1999 for those without a
diagnosis of diabetes. Because some data
were collected before the baseline date of
1 January 1996, there exists the potential
for misclassiﬁcation of confounding vari-
ables. It is also possible that members
switched categories of confounding vari-
ablesbetweenthecompletionoftheirsur-
vey and the end of the study.
Data on physical activity, a potential
confounder of the associations between
diabetes and the pulmonary outcomes,
were,unfortunately,unavailable.Thedif-
ferential diagnosis of pulmonary out-
comes by diabetes status was also a
potential problem, as members with a di-
agnosisofdiabetesarelikelytohavemore
contact with the health plan than those
without. We addressed this issue by re-
stricting our outcome deﬁnition to those
patients requiring hospitalization who
had the pulmonary outcome of interest
listedastheirprimarydischargediagnosis
and those for whom the pulmonary out-
come was listed as their underlying cause
of death, thus minimizing detection bias.
We also included the number of outpa-
tient visits attended in the year before
the baseline in fully adjusted models
and the associations remained statisti-
cally signiﬁcant.
In summary, our results suggest that
patientswithadiagnosisofdiabetesareat
increased risk for asthma, COPD, pulmo-
nary ﬁbrosis, and pneumonia. Future
studies examining the risk of these pul-
monary conditions among patients with
andwithoutdiabetescouldbeneﬁtfroma
prospective design that includes repeated
measurements of smoking, alcohol con-
sumption,BMI,andphysicalactivityover
time.
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